Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25754635 | 0.83 | CHRM5 (0.32) | CHRM5ADRA2C | |
| SCHEMBL25754617 | 0.77 | CHRM5 (0.35) | CHRM5ADRA2C | |
| SCHEMBL25754627 | 0.71 | MEN1 (0.32) | CHRM5ADRA2C | |
| SCHEMBL25754623 | 0.71 | DPP4 (0.31) | CHRM5ADRA2C | |
| SCHEMBL25754625 | 0.71 | DPP4 (0.31) | CHRM5ADRA2C | |
| SCHEMBL25754626 | 0.71 | MEN1 (0.32) | CHRM5ADRA2C | |
| SCHEMBL25754629 | 0.67 | DPP4 (0.34) | — | |
| SCHEMBL27738377 | 0.66 | CHRM5 (0.38) | CHRM5ADRA2C | |
| SCHEMBL7840193 | 0.64 | ADRA2C (0.48) | CHRM5ADRA2CLMNA | |
| SCHEMBL15600813 | 0.64 | LMNA (0.65) | CHRM5LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | CHRM5 4717/4885ADRA2C 4848/4885LMNA 1517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.